This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D56.1 | Synonyms: Thalassemia major, Beta-thalassemia major, Cooley anemia
Severe beta thalassemia (thalassemia major) is the most severe clinical type in the beta thalassemia spectrum and is also classified as transfusion-dependent beta thalassemia (TDT). The term refers to patients in whom severe anemia manifests within the first 1–2 years of life and who require regular transfusions to survive. Since the first clinical description by Cooley and Lee in 1925, patients with this disease died mostly in childhood until the 1970s.
The standardization of regular transfusion therapy in the 1960s–1970s dramatically extended survival in patients with severe beta thalassemia. However, iron overload from chronic transfusion emerged as a new major cause of death, and the introduction of subcutaneous deferoxamine therapy in 1976 partially resolved this problem. In the 1990s, the oral iron chelator deferiprone was introduced, and FDA and EMA approval of deferasirox (Exjade) in 2005–2006 made oral chelation easier.
The success of the first HLA-matched sibling donor hematopoietic stem cell transplantation (HSCT) by the group of Lucarelli et al. in 1982 made curative treatment of severe beta thalassemia possible for the first time. Advances in transplantation technology subsequently improved HSCT outcomes steadily. However, treatment alternatives for patients without an HLA-matched sibling donor remained a challenge for a long time. To fill this gap, clinical trials of gene therapy using lentiviral vectors began in the 2000s; in 2022 the FDA approved betibeglogene autotemcel (Zynteglo), and in 2023 the CRISPR-based exagamglogene autotemcel (Casgevy) received FDA approval, opening a new era in the treatment of severe beta thalassemia.
Severe beta thalassemia is extremely rare in Korea, but with the increase in multicultural families, the number of patients of South Asian and Southeast Asian origin is rising. In Korea, hematopoietic stem cell transplantation is performed as the main curative treatment, and improving clinical access for the domestic introduction of gene therapy is a future task.
Severe beta thalassemia manifests when both alleles of the HBB gene (11p15.4) carry β0 (complete loss of beta-globin synthesis) or β+ variants causing a severe reduction in function. Examples of β0 variants include nonsense variants (codon 39 C→T), frameshift variants (codon 8/9 +G, codon 41/42 -TTCT), and variants causing aberrant splicing (IVS-I-1 G→A). These variants result in little or no translatable mRNA being produced, so beta-globin chain synthesis is completely blocked.
In the severe form, in the absence of genetic factors that maintain HbF (α2γ2) at a persistently high level (hereditary persistence of fetal hemoglobin, HPFH), HbF levels fall sharply after 6–12 months of age and severe anemia develops. When HPFH coexists, the clinical course is milder even with the β0/β0 genotype, and may present as the transfusion-independent intermediate form.
The HBB gene, the genetic basis of severe beta thalassemia, is located at 11p15.4 and is inherited in an autosomal recessive manner. More than 300 pathogenic variants are currently registered, and the predominant variants differ by region and ethnic group. The main variant types contributing to the severe form are ① complete nonsense variants, ② frameshift variants due to single-nucleotide insertion/deletion, ③ variants of the major splice donor site (IVS-I-1), and ④ transcription initiation site variants. These variants fundamentally block the production of functional mRNA.
BCL11A is a key transcription factor that suppresses HbF expression in adulthood. Single nucleotide polymorphisms (SNPs) located in the erythroid-specific regulatory enhancer region of BCL11A (+58 enhancer) significantly modulate HbF levels. This enhancer region is the direct editing target of the current CRISPR/Cas9-based gene therapy (Casgevy). In addition, KLF1 (Krüppel-like factor 1) and MYB are also involved in regulating HbF expression, and therapeutic research targeting them is under way.
The most common severe clinical form of beta thalassemia in Southeast Asian populations is the HbE/β-thalassemia compound genotype. The HbE variant (codon 26, GAG→AAG, βE/β0) is the most common abnormal hemoglobin variant in Southeast Asia, and when combined with a β0 variant it can produce a severe phenotype resembling thalassemia major. Cases of HbE/β-thalassemia have also been reported in patients from multicultural families in Korea.
Worldwide, approximately 30,000–40,000 patients with transfusion-dependent beta thalassemia (TDT) are estimated to be born each year. The total prevalent patient population is estimated at more than 300,000, a large share of whom are concentrated in Middle Eastern and Asian countries. Iran (~1,500 TDT births per year), India (~10,000 TDT births per year), Pakistan (~5,000 TDT births per year), and Thailand (~3,000 TDT/HbE-β-thal births per year) are the major high-burden countries.
Patients with severe beta thalassemia are very rare in Korea and are diagnosed mainly in immigrant families or children of international couples. TDT transplantation outcomes at domestic hematopoietic stem cell transplantation centers are comparable to international levels, but the small number of patients limits center experience. Gene therapies (Zynteglo, Casgevy) are currently not approved in Korea, and institutional efforts are needed to improve patient access.
Worldwide, advances in transfusion and chelation therapy have greatly improved adult survival among patients with severe beta thalassemia. Accordingly, the number of adult TDT patients is increasing, and management of complications specific to adulthood (reproductive health, osteoporosis, thrombosis, psychological burden) has emerged as an important clinical challenge. These changes are creating a turning point in which thalassemia management, previously centered on pediatrics, shifts to internal medicine and adult hematology.
In severe beta thalassemia, ineffective erythropoiesis is the most central pathological mechanism. When beta-globin chain synthesis is lost, excess alpha chains accumulate within erythroid precursor cells (erythroblasts) and form insoluble aggregates. These alpha chain aggregates ① form oxidative cross-links with cell membrane proteins (spectrin, band 3), causing membrane instability, and ② generate reactive oxygen species (ROS), activating the mitochondria-dependent apoptosis pathway. As a result, approximately 70–80% of all erythroid precursor cells produced fail to mature in the bone marrow and die.
The TGF-β (Transforming Growth Factor-beta) signaling pathway plays a key role in the molecular mechanism of ineffective erythropoiesis. In particular, the TGF-β signaling ligands GDF11 and activin A suppress late erythroid differentiation (proerythroblast → orthochromatic erythroblast). Luspatercept (Reblozyl), a drug that blocks this pathway, is an ActRIIA-Fc fusion protein that binds GDF11 and activin B and promotes late erythroid maturation through inhibition of Smad2/3 signaling. This is the mechanism by which luspatercept improves ineffective erythropoiesis and reduces transfusion requirements.
Ineffective erythropoiesis causes oversecretion of erythropoietin (EPO) and erythroferrone (ERFE), and ERFE suppresses hepcidin synthesis in the liver. When hepcidin decreases, ferroportin activation in small intestinal cells increases iron absorption 5- to 10-fold. This mechanism explains why iron overload occurs in severe beta thalassemia independently of transfusion. Minihepcidins or hepcidin analogs are being explored as investigational therapeutics targeting this pathway.
In severe beta thalassemia, intrauterine development is normal because HbF is the main hemoglobin in the fetal period. Symptoms begin to appear between 6 months and 1 year of age, when the switch from HbF to HbA occurs after birth. Early symptoms are gradual pallor, jaundice, poor feeding, poor weight gain, and frequent infections. Parents or medical staff usually notice abnormal signs at 3–6 months of age, and diagnosis is usually made between 6 and 24 months of age.
In patients who do not receive regular transfusions or receive inadequate transfusions, complications of progressive ineffective erythropoiesis develop. Splenomegaly (massive spleen) and hepatomegaly progress rapidly, with abdominal distension and early satiety. Skeletal deformities include skull expansion ('hair-on-end'), maxillary hyperplasia ('chipmunk face'), zygomatic bone enlargement, and thinning of long bone cortex. Growth failure and delayed pubertal development also occur. In patients now receiving regular transfusions these complications have decreased greatly, but they remain a problem in regions with insufficient medical infrastructure.
The main symptoms in regularly transfused patients are complications due to iron overload. Cardiac involvement presents as arrhythmia (palpitations, dizziness, syncope), exercise intolerance, and symptoms of heart failure. Liver involvement can progress to elevated liver enzymes, hepatomegaly, and cirrhosis. Endocrine involvement presents as growth retardation, delayed puberty, diabetic symptoms (polydipsia, polyuria), and hypothyroid symptoms (fatigue, weight gain, cold intolerance). Back pain and pathological fractures due to osteoporosis are also common in adulthood.
Pre-transfusion testing shows severe microcytic hypochromic anemia with Hb 2–7 g/dL. MCV and MCH are markedly decreased, and reticulocytes are increased but relatively low for the degree of anemia owing to ineffective erythropoiesis. Peripheral blood smear shows target cells, nucleated red blood cells, poikilocytes, and bizarrely shaped red blood cells. HPLC shows HbF 10–90% (rising close to 90% in severe β0/β0), loss or marked reduction of HbA, and normal to slightly elevated HbA2.
Serum ferritin rises sharply with chronic transfusion and may reach 5,000–10,000 ng/mL or higher in transfusion-dependent patients. Increased transferrin saturation and elevated serum iron are also seen. Cardiac MRI T2* <20 ms indicates cardiac iron overload, and liver MRI T2* <2.7 ms indicates severe hepatic iron overload. Measurement of liver iron concentration (LIC) shows values greatly exceeding the upper limit of normal (1.8 mg/g dry weight).
X-rays of the skull, spine, and long bones show bone marrow hyperplasia and cortical thinning. On electrocardiography, arrhythmias (QT prolongation, atrial fibrillation) may appear early. If echocardiography shows decreased left ventricular function or dilated cardiomyopathy, urgent intensive chelation is needed. Liver MRI and cardiac MRI T2* imaging are the standard for quantitative assessment of iron overload.
The most effective management of severe beta thalassemia is primary prevention through prevention of affected births. In pregnant women from Mediterranean, Middle Eastern, South Asian, and Southeast Asian backgrounds, β-thal trait carriers are identified by CBC (MCV <80 fL or MCH <27 pg) and HPLC (HbA2 ≥3.5%). The same screening is performed on the partners of carrier pregnant women, and when both partners have β-thal trait, prenatal genetic testing is recommended.
In Iran, the national newborn screening program includes HbF measurement for early identification of thalassemia major. In Italy, Greece, and other countries, newborn screening is also performed in certain high-risk regions. The newborn screening programs of the United States and the United Kingdom screen for abnormal hemoglobinopathies and thalassemia by hemoglobin testing (HPLC). In Korea, severe beta thalassemia is not included in the standard newborn screening panel, but a system for identifying high-risk mothers needs to be established.
In diagnosed patients, regular measurement of Hb, reticulocytes, and serum ferritin before and after transfusion is essential. Cardiac MRI T2* (every 6–12 months) and liver MRI T2* (every 6–12 months) for monitoring iron overload are used to evaluate the effect of chelation therapy and adjust the treatment strategy. Endocrine function tests (growth velocity, thyroid function, blood glucose, reproductive hormones) are also performed regularly.
The key test for diagnosing severe beta thalassemia is hemoglobin analysis by HPLC or capillary electrophoresis. In the β0/β0 genotype, HbF rises to nearly 90%, HbA is lost, and HbA2 is normal to slightly elevated. In the β0/β+ genotype, HbA remains but is markedly reduced. HPLC can simultaneously identify various hemoglobin abnormalities, including HbE/β-thalassemia. The diagnosis is made by integrating these results with clinical findings (severe anemia, age at onset, transfusion dependence).
HBB gene analysis is essential for confirming the diagnosis, genetic counseling, and prenatal diagnosis. In Korea, ARMS-PCR, ethnicity-specific variant panels, Sanger analysis of the entire HBB coding region, or NGS-based hemoglobin disorder panel testing are performed at large medical institutions. For HbE/β-thalassemia, identification of the HBB codon 26 (GAG→AAG) variant is essential. Prenatal diagnosis is performed by CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation).
To assess the degree of iron overload and organ damage at diagnosis and during follow-up, perform ① serum ferritin, ② liver MRI T2* (liver iron concentration, LIC), ③ cardiac MRI T2*, ④ liver function tests (AST, ALT, albumin, prothrombin time), ⑤ echocardiography and electrocardiography, and ⑥ an endocrine function test panel. The results of this assessment determine the choice and intensity of chelation therapy.
Betibeglogene autotemcel (Zynteglo) is the first FDA-approved gene therapy for severe beta thalassemia (FDA approval in August 2022). It is an autologous gene therapy in which the patient's own CD34+ hematopoietic stem cells are collected, the anti-sickling βA-T87Q globin gene is inserted ex vivo using a lentiviral vector (BB305 LV), and the cells are reinfused into the patient. After preconditioning (myeloablative conditioning busulfan chemotherapy), the genetically modified cells are transplanted. In the pivotal clinical trials (HGB-207, HGB-212), more than 90% of patients excluding the β0/β0 genotype achieved transfusion independence, and approximately 70% of β0/β0 patients also achieved transfusion independence. The greatest limitation is the extremely high treatment cost of approximately 2.8 million dollars for a one-time treatment.
Exagamglogene autotemcel (exa-cel, Casgevy, formerly CTX001) is a therapy using CRISPR/Cas9 gene editing and received FDA approval in December 2023 (approved simultaneously for beta thalassemia and sickle cell disease). This therapy edits the erythroid-specific enhancer element of the BCL11A gene (+58 enhancer) with CRISPR/Cas9, suppressing BCL11A expression in erythroid cells and thereby reactivating fetal hemoglobin (HbF). The reactivated HbF binds excess alpha chains and alleviates ineffective erythropoiesis and hemolysis. In the clinical trial (CLIMB THAL-111), 39 of 42 TDT patients (93%) followed for 52 weeks or more achieved sustained transfusion independence. Because it also uses autologous hematopoietic stem cells, it has the advantage of no risk of graft-versus-host disease (GVHD).
Luspatercept (luspatercept-aamt, Reblozyl) is the first erythroid maturation agent, approved by the FDA in 2019. As an ActRIIA-Fc fusion protein, it binds GDF11 and activin B and blocks Smad2/3 signaling that suppresses late erythroid differentiation, thereby improving ineffective erythropoiesis. In the phase 3 clinical trial (BELIEVE), 21.4% of TDT patients reduced their transfusion requirement by 50% or more, compared with 4.5% in the placebo group. It is administered by subcutaneous injection every 3 weeks and is used to reduce the transfusion burden in patients who remain transfusion dependent. It is also effective in non-transfusion-dependent thalassemia (NTDT) for reducing transfusion requirements and improving quality of life.
Allogeneic hematopoietic stem cell transplantation (allogeneic HSCT) is currently the gold standard of curative treatment, with a transplant success rate (cure rate) of 80–90% for HLA-matched sibling donor transplantation. In risk stratification according to the Pesaro classification system (no hepatomegaly, no portal fibrosis, good chelation adherence = class I), class I patients have a long-term survival rate of over 90%. However, only 25–30% of all patients have an HLA-matched sibling donor, so HLA-matched unrelated donor transplantation, cord blood transplantation, and haploidentical transplantation are also increasingly performed. Improved outcomes in haploidentical transplantation (reduced mortality, improved cure rate) have recently been reported.
In patients who cannot receive gene therapy or HSCT, regular transfusion (every 2–4 weeks, maintaining a target Hb ≥9–10 g/dL) and chelation with deferasirox (Exjade/Jadenu, oral, once daily) or deferoxamine (injection) are standard treatment. Single-agent or combination chelation is selected according to the degree of iron overload. Folic acid supplementation (1–5 mg/day), splenectomy (selective indication), and vaccination (essential after splenectomy) are added.
The current life expectancy of patients with severe beta thalassemia receiving appropriate transfusion and iron chelation has been extended to their 40s–60s. This is a dramatic improvement compared with the life expectancy of only 5–10 years before 1975. Since the 2000s, deaths from cardiac siderosis have decreased greatly with the introduction of cardiac MRI T2* monitoring and intensified chelation strategies. However, liver cirrhosis, endocrine complications, osteoporosis, and thrombosis remain important complications.
In patients with successful HSCT, achievement of transfusion independence is accompanied by gradual resolution of iron overload and improved quality of life. In the longest-term data of gene therapy (Zynteglo), followed for more than 9 years, transfusion independence is maintained, and as for safety concerns (the possibility of lentiviral insertional mutagenesis), no clinically significant cases have been reported to date. Long-term follow-up data for Casgevy are currently being accumulated.
Challenges for improving quality of life in surviving adult patients consist of ① reducing the burden of regular transfusion and chelation, ② endocrine replacement therapy (growth hormone, thyroid hormone, sex hormones, insulin), ③ osteoporosis treatment (bisphosphonates, denosumab), ④ psychological support (burden of chronic disease management, reproductive health counseling), and ⑤ support for employment and social integration.
With the advent of gene therapy and CRISPR-based therapy, changes to prevention strategies for severe beta thalassemia are being discussed. In the past, termination of an affected pregnancy after prenatal diagnosis was the core of prevention, but as the era has arrived in which gene therapy can cure the disease, ethical and medical discussions are taking place about a strategy of applying gene therapy after the birth of an affected child. However, given the extremely high cost and limited access of current gene therapy, the importance of prenatal prevention strategies remains valid.
In heterozygous carrier couples, there is a 25% chance of having a child with thalassemia major in each pregnancy. Prenatal diagnosis (CVS or amniocentesis) and preimplantation genetic testing (PGT-M) are the main prevention methods currently available. With the increase in multicultural families, establishing a prenatal screening system for pregnant women from high-risk ethnic backgrounds is also required in Korea.
To prevent complications in diagnosed patients with severe beta thalassemia, the following are recommended: ① maintaining the target transfusion Hb (pre-transfusion ≥9–10 g/dL), ② systematic iron chelation (target serum ferritin <1,000 ng/mL), ③ regular cardiac MRI T2* monitoring (once a year), ④ regular endocrine function testing, ⑤ vaccination (after splenectomy), ⑥ regular bone density testing (dual-energy X-ray absorptiometry every 2 years in adulthood), and ⑦ thrombosis prevention (antiplatelet therapy after splenectomy).